UBS cuts PolyPeptide to neutral, returns hinge on Samsung deal
FROM THE WIRE · FINANCE.YAHOO.COM
Investing.com -- UBS cut Swiss therapeutic-peptide contract manufacturer PolyPeptide Group AG to "neutral" from "buy" because its new CHF 44 price target is now broadly in line with Samsung Biologics' all-cash tender offer of CHF 44.31 per share. Before you buy NVIDIA: our AI…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralUBS believes PolyPeptide's price target already reflects Samsung's offer; returns depend on deal completion.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01UBS downgraded PolyPeptide from buy to neutral with a CHF 44 price target.
- 02Samsung Biologics' all-cash offer is CHF 44.31 per share, valuing PolyPeptide at about CHF 1.46 billion.
- 03Deal completion is targeted by year-end and requires acceptance from 66.7% of shareholders.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
PolyPeptide Group AG43.90 CHF-0.11%today -0.34%Neutral Samsung Electronics Co., Ltd.268,500.00 KRWMarket closedtoday -1.29%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets